The One-carbon Therapeutics team is proud and excited to share our latest paper published in
Nature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitor
TH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificity
and emphasises the importance of utilising correct human-like conditions and cancer models in drug
development. We show that cancer-specific formate overflow drives toxic folate trapping upon
inhibition of cytosolic MTHFD1, leading to cancer cell death.
One-carbon Therapeutics to Present Trial-in-Progress Poster on ODIN Phase 1/2 Study ofTH9619 at the 2026 ASCO Annual Meeting
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage
